Exelixis

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exelixis reports robust Q4 performance, eyes pipeline expansion in 2023

Exelixis showed strong revenue growth and strategic wins in Q4 2022.
The company faces challenges with net losses and gross to net expectations.
Opportunities lie in pipeline advancement, zanzalintinib development, and new business activities.
Overall, Exelixis remains focused on growth and innovation in the pharmaceutical sector.

Exelixis reports strong Q1 earnings, advances promising pipeline programs

Exelixis showcased robust financials and a promising pipeline in Q1, driven by strong CABOMETYX performance and R&D advancements.
Challenges include gross to net impact and delays in share repurchase program purchases, with key decisions pending on XL102 progress.
Opportunities lie in expanding Phase 3 trials, focusing on unmet needs, and maintaining a strategic approach to asset prioritization for future growth.

Exelixis reports robust Q2 earnings, advances pipeline for growth

Exelixis delivered a strong Q2 performance with significant revenue and income figures, driven by the success of CABOMETYX and ongoing R&D efforts.
The company's market leadership, legal resolution with Teva, and commitment to innovation position it well for future growth and competitive advantage.
While facing challenges in program decision-making and market penetration, Exelixis has opportunities in pipeline advancement, regulatory discussions, and investor engagement.
Overall, Exelixis remains focused on its mission to help cancer patients, with a positive outlook and strategic initiatives in place for continued success.

Exelixis reports strong Q3 earnings, faces guidance challenges and growth opportunities

Exelixis had a strong Q3 2023 with robust revenue growth from CABOMETYX and ongoing operational support.
The company faces challenges in financial guidance adjustments and questions on FDA expectations and legal proceedings.
Opportunities lie in potential growth for CABOMETYX, advancing pipeline assets, and expanding into new indications.
Overall, Exelixis remains focused on innovation, collaboration, and supporting cancer patients with upcoming R&D Day excitement.

Exelixis reports robust 2023 performance, eyes growth through collaborations

Exelixis had a strong financial performance in 2023, driven by the cabozantinib franchise and strategic initiatives.
While facing challenges such as access to therapies and treatment variations, the company is well-positioned for growth.
Opportunities lie in collaborations, regulatory progress, and innovative drug development, positioning Exelixis for future success.

Exelixis reports strong Q1 earnings, focuses on pipeline advancement

Exelixis had a robust Q1 2024 with revenue and demand growth for Cabozantinib franchise.
Company is focused on advancing new indications, returning capital to shareholders, and pipeline development.
Challenges include study criteria, market capture, and capital allocation decisions.
Exciting opportunities lie in Zanza's potential, new combinations, and market growth prospects.

Exelixis excels in Q2 with cabozantinib driving revenue growth

Exelixis delivered a strong Q2 performance driven by cabozantinib franchise. Despite challenges in a competitive landscape, the company's focus on pipeline assets and commercial success presents growth opportunities. With increased revenue guidance and strategic initiatives, Exelixis is poised for continued success.

Exelixis excels in Q3 2024 with revenue growth and increased guidance

Exelixis delivered a strong performance in Q3 2024, marked by revenue growth, profitability, and increased guidance for the full year. The company's financial stability, strategic focus on oncology, and strong cash position provide a solid foundation for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Shares of Exelixis (NASDAQ:EXEL) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 46.15% over the past year to $0.14, which beat the estimate of $0.05.

Recap: Exelixis Q4 Earnings

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and full year 2020 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones. “I'm very proud of the Exelixis team's execution in the fourth quarter and full year 2020 as we advanced all components of our business to enable top-line revenue growth in 2021 and beyond,” said Michael M. Morris

Exelixis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) will host an investor briefing to discuss data presented at the American Society of Clinical Oncology's 2021 Genitourinary Cancers Symposium (ASCO GU 2021). The online-only event will be held on Saturday, February 13, 2021, beginning at 5:30 p.m. EST / 2:30 p.m. PST. During the briefing, Exelixis management and invited guests from the clinical community will discuss and provide context for cabozantinib clinical data presented at AS

Exelixis to Host Investor Briefing to Discuss Data Presented at the American Society of Clinical Oncology's 2021 Genitourinary Cancers Symposium

Bristol-Myers

Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) have announced updated data from Phase 3 CheckMate 9ER trial, evaluating the combination of former's Opdivo (nivolumab) and latter's Cabometyx (cabozantinib) drug compared to Pfizer Inc's (NYSE: PFE) Sutent (sunitinib) in the first-line treatment of advanced renal cell carcinoma. BMY will present the data at the virtual American Society of Clinical Oncology 2021 Genitourinary Cancers Symposium.

Opdivo Plus Cabometyx Combo Shows Superior Clinical Benefit Versus Sunitinib In Late-Stage Kidney Cancer Study

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced results from a retrospective analysis evaluating CABOMETYX® (cabozantinib) activity in brain metastases in patients with renal cell carcinoma (RCC). The findings will be presented as part of the Poster Session: Renal Cell Cancer at the 2021 American Society of Clinical Oncology's Genitourinary Cancers Symposium (ASCO GU), which is being held virtually, February 11-13, 2021. All posters will be available on demand be

Exelixis Announces Positive Findings at ASCO GU for CABOMETYX® (cabozantinib) in Patients with Brain Metastases from Renal Cell Carcinoma

Investors will focus on pipeline and guidance updates when Exelixis (EXEL) reports fourth-quarter 2020 results.

Exelixis (EXEL) to Report Q4 Earnings: What's in the Cards?

Coherus BioSciences

Dynavax Technologies

Illumina

I-Mab

Eli Lilly

Week In Review: Junshi Signs $1.1 Billion Deal For U.S.-Canada Rights To PD-1

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer will participate in a fireside chat as part of the Guggenheim Healthcare Talks Oncology Day on Thursday, February 11, 2021 at 11:30 AM EST / 8:30 AM PST. Due to the ongoing COVID-19 pandemic, the conference will be held as a virtual event. To access the webcast link, log onto www.exelixis.com and proceed to the News & Events /

Exelixis to Webcast Virtual Fireside Chat as Part of the Guggenheim Healthcare Talks Oncology Day on February 11, 2021

Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Exelixis (EXEL) Q4 Earnings Expected to Decline

ALAMEDA, Calif., SAN FRANCISCO & SUZHOU, China--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Adagene today announced a collaboration and license agreement under which Exelixis will utilize Adagene's SAFEbody™ technology platform to generate masked versions of monoclonal antibodies from Exelixis' growing preclinical pipeline for the development of ADCs or other innovative biologics against Exelixis-nominated targets. Under the terms of the agreement, Exelixis will make an upfront payment o

Exelixis and Adagene Enter into Collaboration and License Agreement to Develop Novel Masked Antibody-Drug Conjugate Therapies with Improved Safety and Efficacy Profiles

AstraZeneca

Datadog

EverBank Financial

Growth stocks have run circles around value stocks for more than a decade, and that trend is likely to continue.

Got $4,000? 4 Growth Stocks Begging to Be Bought

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2020 financial results will be released on Wednesday, February 10, 2021 after the markets close. At 5:00 p.m. EST / 2:00 p.m. PST, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the webcast link, log onto www.exelixis.

Exelixis to Release Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 10, 2021

Exelixis (EXEL) obtains FDA approval for Cabometyx in combination with immuno-oncology drug, Opdivo, for the first-line treatment of patients with advanced kidney cancer.

Exelixis (EXEL) Wins FDA Nod for Cabometyx + Opdivo in RCC

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced initiation of the first-in-human phase 1 trial evaluating the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of XL102 alone or in combination with other anti-cancer agents in patients with inoperable locally advanced or metastatic solid tumors. XL102 is a potent, selective and orally bioavailable inhibitor of cyclin-dependent kinase 7 (CDK7), an important regulator of the cell cycle that

Exelixis Announces Initiation of Phase 1 Trial Evaluating XL102 as a Single Agent and in Combination with Other Anti-Cancer Agents in Patients with Advanced or Metastatic Solid Tumors

The regulator's nod represents an important expansion for the drug.

Exelixis Gets FDA Approval for Cabometyx in Combination Therapy for Front-Line RCC

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX® (cabozantinib) for patients with advanced renal cell carcinoma (RCC) as a first-line treatment in combination with OPDIVO® (nivolumab). RCC is the most common form of kidney cancer, which is among the 10 most frequently diagnosed cancers in the U.S. annually.1 “This combination of cabozantinib and nivolumab significantly improved key efficacy measu

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma

Ping Identity Holding Corp

SSR Mining

White Mountains Insurance Group

These companies offer the perfect blend of growth and value.

5 Mid-Cap Stocks That'll Make You Richer in 2021

Fastly

Intuitive Surgical

OrganiGram Holdings Inc.

Visa

Buying and holding innovative businesses is a time-tested way to build wealth.

Who's Ready to Get Rich? 5 Moneymaker Stocks to Buy Now

Exelixis, Inc. (EXEL) Management Presents at 39th Annual J.P. Morgan Healthcare Conference (Transcript)

Exelixis (EXEL) provides preliminary results for the fourth quarter and 2020 along with the annual guidance for 2021. It also throws light on anticipated milestones for 2021.

Exelixis (EXEL) Reports Preliminary Q4 Results, Business Updates

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fourth quarter and full year 2020, provided financial guidance for full year 2021, and delivered an update on its business. This 2021 financial guidance takes into consideration the anticipated U.S. Food and Drug Administration (FDA) approval and commercial launch of CABOMETYX® (cabozantinib) in combination with OPDIVO® (nivolumab) as a first-line treatment for pat

Exelixis Announces Preliminary Fourth Quarter and Full Year 2020 Financial Results, Provides 2021 Financial Guidance, and Outlines Key Priorities and Anticipated Milestones For 2021

Novavax

Vertex Pharmaceuticals

One big biotech and two small biotechs that share a common denominator: Great growth prospects.

3 Top Biotech Picks for 2021

Yamana Gold

Teva Pharmaceutical

Walgreens

Wells Fargo

Bargains are plentiful for value investors in the new year.

5 Value Stocks That Will Make You Richer in 2021

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview at the virtual 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 5:20 p.m. EST / 2:20 p.m. PST. To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the

Exelixis to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021

Teladoc

Here's your prescription for huge returns in the upcoming year.

News for Exelixis Stock (EXEL)